TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Aprea Therapeutics ( (APRE) ) has provided an announcement.
On September 8, 2025, Aprea Therapeutics updated its corporate presentation, highlighting its progress in clinical trials and development milestones for its product candidates, including ATRN-119 and APR-1051. The announcement underscores Aprea’s strategic focus on advancing its DDR inhibition therapies, with promising early clinical activity observed in ongoing trials, which may enhance its position in the oncology market.
The most recent analyst rating on (APRE) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.
Spark’s Take on APRE Stock
According to Spark, TipRanks’ AI Analyst, APRE is a Underperform.
Aprea Therapeutics receives a low overall score due to significant financial challenges, including consistent losses and lack of revenue generation. The company’s strong balance sheet is a positive but is offset by negative cash flows and a reliance on external financing. Technical indicators suggest a bearish trend, and the valuation is unattractive due to a negative P/E ratio and no dividend yield.
To see Spark’s full report on APRE stock, click here.
More about Aprea Therapeutics
Aprea Therapeutics, Inc. operates in the biotechnology industry, focusing on precision oncology through synthetic lethality. The company is dedicated to transforming DNA damage response (DDR) inhibition into patient benefits, with a robust development pipeline targeting multiple pathways and offering targeted therapies.
Average Trading Volume: 50,884
Technical Sentiment Signal: Sell
Current Market Cap: $9.03M
For a thorough assessment of APRE stock, go to TipRanks’ Stock Analysis page.